Ernexa Therapeutics (ERNA)
Develops off-the-shelf engineered iMSC therapies for cancer and autoimmune disease.
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
Ernexa Therapeutics Inc. (NASDAQ:ERNA) on Wednesday said an independently conducted preclinical study validated the anti-tumor activity of its lead cell therapy candidate, ERNA-101, when combined with PD-1 checkpoint inhibition, reinforcing earlier findings.
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated off-the-shelf iMSC platform and progress toward planned first-in-human clinical evaluation IND submission planned for the third quarter of 2026 with first-in-human Phase 1 study anticipated to begin in the fourth quarter of 2026 Access the Ernexa CEO Corner here CAMBRIDGE, Mass.
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
CAMBRIDGE, Mass. , May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced significant progress in the development of ERNA-101, the company's lead therapeutic candidate, achieving multiple critical milestones that position the program for a planned Investigational New Drug (IND) submission in the third quarter of 2026 and the anticipated initiation of its first-in-human clinical study.
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.
Ernexa Stock Is Jumping Today: What's Going On?
Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are skyrocketing Tuesday. The market is seemingly reacting to the company's latest investor segment featuring Chief Scientific Officer Dr. Robert Pierce, along with fresh attention on the potential of ERNA‑101 in ovarian cancer.
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced new preclinical data demonstrating that its lead cell therapy candidate, ERNA-101, in combination with PD-1 blockade, drives complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models.
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-25, effective May 4, 2026 at 12:01 a.m.
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer
Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update
Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) saw a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 247,054 shares, a growth of 136.9% from the February 12th total of 104,299 shares. Currently, 3.3% of the company's shares are sold short. Based on an
Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 11.4% – Time to Sell?
Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) shares were down 11.4% during trading on Monday. The company traded as low as $0.2703 and last traded at $0.2703. Approximately 1,070,042 shares were traded during trading, a decline of 65% from the average daily volume of 3,040,254 shares. The stock had previously closed at $0.3051.
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of $0.50 per share (or per common stock equivalent in lieu thereof) and accompanying warrant.